Cargando…
The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
Malignant pleural mesothelioma (MPM) is an aggressive asbestos related disease that is generally considered to be difficult to diagnose, stage and treat. The diagnostic process is continuing to evolve and requires highly skilled pathology input, and generally an extensive list of biomarkers for defi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509088/ https://www.ncbi.nlm.nih.gov/pubmed/33014860 http://dx.doi.org/10.3389/fonc.2020.01742 |
_version_ | 1783585531099086848 |
---|---|
author | Rozitis, Eric Johnson, Ben Cheng, Yuen Yee Lee, Kenneth |
author_facet | Rozitis, Eric Johnson, Ben Cheng, Yuen Yee Lee, Kenneth |
author_sort | Rozitis, Eric |
collection | PubMed |
description | Malignant pleural mesothelioma (MPM) is an aggressive asbestos related disease that is generally considered to be difficult to diagnose, stage and treat. The diagnostic process is continuing to evolve and requires highly skilled pathology input, and generally an extensive list of biomarkers for definitive diagnosis. Diagnosis of MPM requires histological evidence of invasion by malignant mesothelial cells often confirmed by various immunohistochemical biomarkers in order to separate it from pleural metastatic carcinoma. Often when invasion of neoplastic mesothelial cells into adjacent tissue is not apparent, further immunohistochemical testing - namely BAP1 and MTAP, as well as FISH testing for loss of p16 (CDKN2A) are used to separate reactive mesothelial proliferation due to benign processes, from MPM. Various combinations of these markers, such as BAP1 and/or MTAP immunohistochemistry alongside FISH testing for loss of p16, have shown excellent sensitivity and specificity in the diagnosis of MPM. Additionally, over the recent years, research into epigenetic marker use in the diagnosis of MPM has gained momentum. Although still in their research stages, various markers in DNA methylation, long non-coding RNA, micro RNA, circular RNA, and histone modifications have all been found to support diagnosis of MPM with generally good sensitivity and specificity. Many of these studies are however, limited by small sample sizes or other study limitations and further research into the area would be beneficial. Epigenetic markers show promise for use in the future to facilitate the diagnosis of MPM. |
format | Online Article Text |
id | pubmed-7509088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75090882020-10-02 The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review Rozitis, Eric Johnson, Ben Cheng, Yuen Yee Lee, Kenneth Front Oncol Oncology Malignant pleural mesothelioma (MPM) is an aggressive asbestos related disease that is generally considered to be difficult to diagnose, stage and treat. The diagnostic process is continuing to evolve and requires highly skilled pathology input, and generally an extensive list of biomarkers for definitive diagnosis. Diagnosis of MPM requires histological evidence of invasion by malignant mesothelial cells often confirmed by various immunohistochemical biomarkers in order to separate it from pleural metastatic carcinoma. Often when invasion of neoplastic mesothelial cells into adjacent tissue is not apparent, further immunohistochemical testing - namely BAP1 and MTAP, as well as FISH testing for loss of p16 (CDKN2A) are used to separate reactive mesothelial proliferation due to benign processes, from MPM. Various combinations of these markers, such as BAP1 and/or MTAP immunohistochemistry alongside FISH testing for loss of p16, have shown excellent sensitivity and specificity in the diagnosis of MPM. Additionally, over the recent years, research into epigenetic marker use in the diagnosis of MPM has gained momentum. Although still in their research stages, various markers in DNA methylation, long non-coding RNA, micro RNA, circular RNA, and histone modifications have all been found to support diagnosis of MPM with generally good sensitivity and specificity. Many of these studies are however, limited by small sample sizes or other study limitations and further research into the area would be beneficial. Epigenetic markers show promise for use in the future to facilitate the diagnosis of MPM. Frontiers Media S.A. 2020-09-09 /pmc/articles/PMC7509088/ /pubmed/33014860 http://dx.doi.org/10.3389/fonc.2020.01742 Text en Copyright © 2020 Rozitis, Johnson, Cheng and Lee. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Rozitis, Eric Johnson, Ben Cheng, Yuen Yee Lee, Kenneth The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title | The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title_full | The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title_fullStr | The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title_full_unstemmed | The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title_short | The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review |
title_sort | use of immunohistochemistry, fluorescence in situ hybridization, and emerging epigenetic markers in the diagnosis of malignant pleural mesothelioma (mpm): a review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509088/ https://www.ncbi.nlm.nih.gov/pubmed/33014860 http://dx.doi.org/10.3389/fonc.2020.01742 |
work_keys_str_mv | AT rozitiseric theuseofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT johnsonben theuseofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT chengyuenyee theuseofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT leekenneth theuseofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT rozitiseric useofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT johnsonben useofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT chengyuenyee useofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview AT leekenneth useofimmunohistochemistryfluorescenceinsituhybridizationandemergingepigeneticmarkersinthediagnosisofmalignantpleuralmesotheliomampmareview |